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Abstract Induced pluripotent stem cells (iPSCs) are routinely
produced from dermal fibroblasts, with potential applications
ranging from in vitro disease models to drug discovery and
regenerative medicine. The need of eliminating the remaining
reprogramming factors after iPSC production spurred the de-
velopment of non-integrating viruses such as Sendai and other
methods to deliver episomal vectors, which are progressively
lost upon cell division.We compared four widespreadmethods
(Sendai virus, Nucleofector, Neon transfection system and
Lipofectamine 3000) to generate integration-free iPSC lines
from primary human dermal fibroblasts (hDF) of three pa-
tients. Furthermore, we performed extensive characterization
of the iPSC lines. We were able to produce iPSC lines with all
tested methods with variable efficiency. Sendai virus method
achieved the overall highest reprogramming rate, followed by
electroporation-based methods Nucleofector and Neon trans-
fection systems. Chemical-based Lipofectamine 3000 delivery
resulted in the lowest number of iPSC colonies. We found the
reprogramming rate to be intrinsically dependent on the indi-
vidual hDFs but the amenabili ty of each hDF to
reprogramming showed consistency between methods.
Regardless of the reprogramming strategy, iPSCs obtained
did not reveal any significant differences in their morphology,
expression of pluripotency markers, EB formation, karyotype
or gene expression profiles.
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Introduction
Induced pluripotent stem cells (iPSCs), which show an exten-
sive capability for self-renewal, reproduction and differentia-
tion potential overlapping that of embryonic stem cells (ESCs)
can be generated from terminally differentiated cells with a
defined cocktail of chemical and/or genetic factors [1].
Patient-specific iPSCs hold enormous potential for disease
modeling, cell-based therapies and possibly future organ-
based therapies [2–4].
Early methods of iPSC production resulted in the random
integration into the host genome of the exogenous
reprogramming vectors in iPSCs, leading to increased tumor
formation and mortality in mice generated from these cells,
raising concerns about safety [5]. To tackle them, safer
methods have been developed which make use of episomal
plasmids that can be delivered by non-integrating viruses
(Sendai), electroporation or chemical methods [6]. Residual
safety concerns and cost-related issues of virus-based
reprogramming still make the use of simpler methods attrac-
tive. These methods rely on electrical current or chemical com-
pounds to deliver the reprogramming factors into somatic cells.
They are reportedly less efficient in reprogramming but can be
employed more broadly and do not require dedicated labora-
tory space and Biosafety Committee review and approval. In
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the present report we focused on four popular methods (Sendai
virus, Nucleofector and Neon Electroporation Systems, and
Lipofectamine 3000), which are widely employed in laborato-
ries, and compared their efficiency in reprogramming patient-
derived primary human dermal fibroblasts (hDF) into iPSCs.
All methods were used to reprogram hDFs originating from
three different patients to take variability into account. Finally,
we also characterized the iPSC lines for pluripotency by PCR,
immunocytochemistry and embryoid body (EB) formation, as
well as for karyotype.
Materials and Methods
Isolation of Dermal Fibroblasts and Cell Culture
A skin biopsy of approximately 3 mm was collected from the
patients (Ethical approval number R12123) by a trained health
care professional. Primary human dermal fibroblasts (hDFs)
were obtained by explantation from the skin samples and the
cells were grown in Fibroblast Medium, containing DMEM
(Life Technologies) supplemented with 10 % FBS (Sigma
Aldrich), penicillin/streptomycin and L-glutamine (Lonza),
medium was refreshed every 2–3 days and fibroblasts were
split 1:2–1:4 when they reached ca. 80 % confluence.
Established colonies were cultured in knockout serum re-
placement (KSR) medium using mouse embryonic fibroblasts
(MEF; Millipore, Billerica, MA) as feeders. The components
of KSR medium are: knockout (KO)-DMEM (Life
Technologies) containing 20 % KO-serum replacement (KO-
SR, Life Technologies), nonessential amino acids (NEAA),
g lu tamine , pen ic i l l in / s t r ep tomyc in , 0 .1 mM 2-
mercaptoethanol and 4 ng/ml fibroblast growth factor 2
(FGF2) (bFGF, R&D Systems Inc., Minneapolis, MN,
USA). The medium was refreshed three times a week.
The hESC line H7 (46, XX) (WiCell Research Institute,
Madison, WI, USA) was used as a comparison in the immu-
nocytochemical stainings and PCR for pluripotency [7].
Reprogramming of Fibroblasts to iPSCs
Plasmid VectorsVectors are available on Addgene repository
upon request: 27,077 (pCXLE-hOCT3/4-shp53-F); 27,078
(pCXLE-hSK); 27,080 (pCXLE-hUL) and 37,624
(pCXWB-EBNA1) [8]. Plasmid DNA cocktail contained the
four vectors in equimolar amounts (1:1:1:1).
Sendai Virus Reprogramming 150,000 fibroblasts were
transduced with Sendai virus vectors following CytoTune®-
iPS Sendai Reprogramming Kit’s guidelines, at a MOI of 1.25.
Lipofectamine Transfection Fibroblasts at 80–90 % conflu-
ence growing in 6-well plates wells were transfectedwith 7.5μl
Lipofectamine 3000 reagent, 5 μl P3000 and 2.5 μg of plasmid
DNA cocktail, following manufacturer’s instructions.
Neon Transfection SystemHuman fibroblasts (6 × 105) were
transfected with the Neon Transfection System (Life
Technologies) according to manufacturer’s instructions.
Conditions used were 1650 V, 10 ms, 3 time pulses, with a
total of 3 μg plasmid DNA cocktail.
Nucleofector System Human fibroblasts (6 × 105) were
transfected with the 4D-Nucleofector™ System (Lonza) ac-
cording to manufacturer’s instruction, preset [EO114], with
3 μg plasmid DNA cocktail.
After Lipofectamine 3000, Neon or Nucleofector transfec-
tion and Sendai virus transduction, fibroblasts were cultured
for 7 days in Fibroblast Medium, then trypsinized and re-
plated onto 6-well plates wells layered with MEF feeder cells.
The culture medium was switched the next day to KSR sup-
plemented with bFGF.
Characterization of iPSC Lines
DNA and RNA Extraction Nucleospin Tissue XS kit
(Macherey-Nagel) and RNeasy Mini Kit (Qiagen) have been
respectively used to extract DNA and RNA, following manu-
facturers' instructions.
RT-PCR and PCRTotal RNA (1 μg) was reverse transcribed
with High Capacity cDNA Reverse Transcription Kit (Life
Technologies) and random hexamers, following the manufac-
turer’s protocol. RT reaction without Reverse Transcriptase
enzyme served as internal control. PCR was performed on
30 ng cDNA or 25 ng gDNA, with primer pairs indicated in
Table S1, with DyNAzyme II TAQ DNA Polymerase (Life
Technologies). We used the H7 line as a positive control for
pluripotency.
In Vitro Analysis of Pluripotency The pluripotency of the
iPSC lines UTA.11916.EURCSs, UTA.137062.EURCSp,
UTA.107016.EURCAp and UTA.119024.EURCSp was veri-
fied by the formation of embryoid bodies (EBs). To form EBs,
feeder cells were removed mechanically and iPSCs were
scraped and placed into a suspension culture in EB medium
(KO-DMEM with 20 % FBS, Non-Essential Amino Acid
(NEAA), L-glutamine and penicillin/streptomycin). Medium
was refreshed every 2 to 3 days, and EBs were cultured for
5 weeks after which RNA isolation and reverse transcription
from the EBs was performed as described above. The expres-
sion of markers characteristic of ectoderm (PAX6 or SOX-1),
endoderm (AFP or SOX-17), and mesoderm (KDR or
ACTC1) development were studied from EBs and GAPDH
was used an endogenous control. PCR primers for detecting
the aforementioned genes are presented in Table S1.
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Karyotyping Genome-wide screening for gross chromosom-
al abnormalities was carried out with KaryoLite BoBs
(Product number 4501–0010, Perkin Elmer) in the Finnish
Microarray and Sequencing Centre, as described elsewhere
[9]. The assay measures DNA copy numbers at the chromo-
some arm resolution, by evaluating the signal of bacterial
artificial chromosomes (BACs) immobilized onto color-
encoded polystyrene beads, detectable by a Luminex fluorom-
eter. 97 individual beads cover p and q arms of all chromo-
somes 1–22, X and Y (q arms in acrocentric chromosomes)
and can detect arm-specific aneuploidies in all 24 chromo-
somes in a single assay.
Immunocytochemistry The cells were washed three times
with room temperature PBS. After removing PBS, the cells
were fixed for 20min with room temperature 4% PFA (Sigma
Aldrich) to prevent cell detachment, and unspecific binding
was blocked for 45 min with 1 % bovine serum albumin
(BSA), 0.1 % Triton X-100 (Sigma Aldrich), 10 % normal
donkey serum (NDS,Millipore) in 1X PBS. Blocking solution
was removed with 1 % NDS, 0.1 % TritonX-100 and 1 %
BSA in PBS 1X, then primary antibodies diluted in the same
solution were incubated overnight at +4 °C.
The primary antibodies included pluripotency markers
Nanog (Anti-human Nanog goat IgG; R&D Systems, Inc)
1:100; Oct-3/4 (Anti-human Oct.-3/4 goat IgG; R&D
Systems, Inc.) 1:400; SOX-2 (SOX-2 goat IgG; Santa Cruz)
1:200; SSEA-4 (SSEA-4 mouse IgG; Santa Cruz) 1:100;
TRA-1–60 (Anti-TRA 1–60 mouse IgM; Millipore) 1:200;
and TRA 1–81 (Anti-TRA 1–81 mouse IgM; Millipore)
1:200. Secondary antibodies, 1:800 in 1 % BSA in PBS 1X,
were incubated for 1 h at RT, protected from light, and includ-
ed Alexa Fluor 568 nm donkey anti-goat IgG (Invitrogen) for
Nanog, Oct-3/4 and Sox-2; Alexa Fluor 568 nm goat anti-
mouse IgG H&L (Invitrogen) for SSEA-4; and Alexa Fluor
568 nm goat anti-mouse IgMM chain (Invitrogen) for TRA 1-
60 and TRA 1-81. Samples were mounted with Vectashield
Mounting Medium with DAPI (Vector Laboratories). Images
were captured with fluorescence microscope (Olympus IX51)
connected to a camera (Olympus DP30BW) and processed
with DP manager software (Olympus).
Results and Discussion
Reprogramming Efficiency
The greatest hurdle in reprogramming terminally differentiated
cells into iPSCs is reprogramming efficiency.Manymethods of
reprogramming are inefficient yielding iPSCs inmuch less than
1 % of the starting adult cells. To overcome this limitation
many methods have been developed involving the use of vi-
ruses and/or chemicals to enhance reprogramming efficiency at
the cost of safety and resources. The use of non-integrating
viruses, such as the Sendai virus, delivering episomal vectors
for reprogramming has enhanced the safety of the method
maintaining a high reprogramming efficiency. Still, Sendai-
based commercial kits are expensive and do require separate
laboratory space (biosafety level 2) and dedicated equipment
for virus work. Furthermore, the episomal vectors contained in
the kits are patented and their sequence is not available, even
though it is known what reprogramming factors they encode
for. This also limits the research and testing of additional
reprogramming cocktails. Non-integrating vectors are freely
available and are amenable to being modified and/or used in
custom formulations. They can be delivered by standard
chemical transfection or electroporation, but these methods
reportedly show lower efficiency rates.
Fibroblasts are the cell type most widely used in
reprogramming. Even if other types of terminally differentiat-
ed cells have been shown to be more amenable for
reprogramming than skin fibroblasts, the latter are easily col-
lected and managed and remain nowadays the primary source
of cells for reprogramming [9, 10].
We chose to test the most widely used methods for gener-
ating iPSC lines from dermal fibroblasts (hDF) of three differ-
ent patients (hDF 107, 137 and 119), to compare their
reprogramming efficiency and take into account the variability
of real-world patients.
As expected, Sendai-virus based reprogramming was over-
all the most efficient method (0.0026 %, 0.04 % and 0.0173 %
efficiency for hDFs 107, 137 and 119, respectively (Fig. 1A).
Nucleofector showed the most robust performance and good
reprogramming efficiency (0.017 %, 0.0166 % and 0.003 %),
compared to Neon electroporation (2.7·10−5%, 0.0044 % and
5.5·10−5% for hDFs 107, 137 and 119, respectively). As
expected, the method based on chemical delivery
(Lipofectamine 3000) showed the lowest reprogramming
efficiency being able to successfully reprogram only hDF 137
(0.001%). This is in line with the results obtainedwith the other
methods as hDF 137 showed the highest overall
reprogramming rate. It can be speculated that properly
reprogrammed colonies could be obtained by raising the
number of fibroblasts transfected. Colonies obtained with any
of the methods showed similar phenotype (Fig. 1B-K).
Cell type and differentiation stage have been shown to
influence reprogramming efficiency [11]. Epigenomic state,
genetic variability and stochastic mechanisms all play a role
in defining individual cell line’s response to reprogramming
[12]. Notably, primary fibroblasts showed differences in the
reprogramming efficiency, consistent between methods
(Fig. 1). hDFs 107 and 119 showed decreased reprogramming
efficiency, and failed to produce viable iPSCs-like colonies
with Lipofectamine 3000 transfection in our experimental set-
ting. hDF 137 was more amenable to reprogramming and
produced colonies with good efficiency with all methods
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(0.04 %, 0.0166 %, 0.0044 and 0.001 % with Sendai,
Nucleofector, Neon and Lipofectamine 3000 respectively).
Interestingly, by using the Nucleofector we were able to effi-
ciently reprogram hDF 107 at higher efficiency than by using
any of the other methods..
Methods showed small differences in the average number
of days when colonies appeared to be ready for picking
(Fig. 2A). On average, most colonies were picked ~25 to
~30 days post transfection/transduction. Lipofectamine 3000
resulted in colonies which could be picked on average at day
24 post transfection, up to day 28; electroporation produced
colonies which could be picked, on average, as early as 22–
25 days post transfection, with Sendai-reprogrammed colonies
trailing shortly after at day 29. The viable period for picking
colonies, for each method, has been ~ ±3 days around the
average picking day, with small differences between methods.
We hypothesize that the variability of the individual operator
could have a deeper impact than any other intrinsic variable.
Gene Expression and Plasmid Contamination
Of all picked colonies, some failed to develop further upon
replating onto feeder layer, or showed signs of differentiation
































Fig. 1 Human fibroblast
reprogramming. Human dermal
fibroblasts (hDF) from three
different patients
(hDF 107, 119 and 137) were
reprogrammed into iPSC lines by
using four different methods
(Sendai virus, Nucleofector, Neon
transfection system and
Lipofectamine 3000) to deliver
the reprogramming plasmids.
Average reprogramming
efficiency of the four methods
used is presented for each hDF
(a). Reprogramming efficiency is
expressed in nascent colonies per
cells transduced/transfected and
the scale in the plot is logarithmic.
Pictures of iPSCs colonies at
different passage numbers are
shown, each representative of a
different condition: colonies are
starting to grow on top of MEFs
two weeks after transfection of
hDF 137 (b), and colonies at
passage 1 are shown in (c);
Cytotune Sendai Reprogramming
kit, at passage 9 from hDF 119
(d); Nucleofector Transfection
System, at passage 4 from hDF
107 (e), hDF 119 (f) and hDF 137
(g); Neon Transfection System at
passage 8 from hDF 107 (h),
passage 5 from hDF 119 (i) and
hDF 137 (j). iPSCs obtained from
hDF 137, at passage 6 with
Lipofectamine 3000 (k)
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showed dependency on the method; Sendai virus resulted in
0 % to 20 % abortive colonies, Nucleofector transfection
ranged from 30 % to 45 %, Neon transfection ranged from
0 % to 45 % and finally Lipofectamine from 33 % to 100 %
(data not shown). Specifically, it was possible to obtain
colony-like structures budding out of the feeder layer with
Lipofectamine 3000 for hDFs 107 and 119, but they failed
to develop further upon replating.
Fig. 2 iPSC colony picking
times and karyotype analyses of
four iPSC lines originating
from one patient. (a)
Comparison of the average time
(dark bar) from the initial
transfection or transduction of the
primary hDF cell lines to the
picking day. Green bars show the
earliest day of picking, red bars
show the latest day for each
method. The number of
independent reprogramming
rounds was three for each method,
where at least 600,000 hDF per
patient were lipofected, 900,000
hDF per patient were
electroporated with either Neon or
Nucleofector systems, and
150,000 hDF per patient were
transduced with Sendai virus in
each reprogramming. (b)
Karyotype analyses of
representative colonies, all derived
from the same patient (hDF 137)
with different methods, are shown.
Red and blue dots indicate
chromosomal signal ratios of
sample DNA against female (red)
and male (blue) reference normal
karyotype DNA, as detected by
KaryoLiteTM BoBs™ assay.
Signal from normal chromosomes
against both male and female
references should lie inside the
reference area around value 1,
whereas with an abnormal
karyotype both signals lie outside
the reference area. A female probe
pattern is defined when X and Y
probe ratios are included in the
expected range for a female
sample (red line/dots inside and
blue line/dots outside the normal
expected X/Y range); a male
pattern is defined by a reverse
pattern (blue line/dots inside and
red line/dots outside the normal
expected X/Y range). Each plot
shows the signal of two technical
replicates of the same sample. All
colonies show a normal male
karyotype
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Colonies that showed correct phenotype upon repeated
passaging were selected for further characterization, each col-
ony giving rise to an iPSC cell line. We investigated the ex-
pression of pluripotency genes in iPSCs cell lines with differ-
ent passage numbers. All iPSCs lines tested expressed the
pluripotency markers NANOG, REX1, SOX2, c-MYC and
OCT3/4 (Fig. 3a). As an expression control, a commercially
available human embryonic stem cell line H7 was used
(Fig. 3b). A possible genomic DNA contamination in the
RNA samples has been ruled out by primer design and by
performing the PCR reaction on RNA without reverse tran-
scription on the reference gene GAPDH (Fig. 3A) and on
the pluripotency markers (data not shown).
Furthermore, we confirmed by immunocytochemical stain-
ing the expression of completely reprogrammed human
pluripotent stem cell markers. iPSC colonies were found pos-
itive for OCT4, SOX2, SSEA-4, TRA 1–60 and TRA 1–81
antigens, without noticeable differences between methods
(Fig. 4) or when compared to H7 hESC line (Fig. S1).
Next, we wanted to estimate plasmid loss. All episomal
plasmids encode for EBNA-1, an Epstein-Barr virus derived
protein, which can enhance the maintenance of circular DNA
vectors harboring an OriP sequence in eukaryotic nuclei [13].
It is estimated that such episomal vectors have 2 % to 5 %
chance of being lost at each cell division [14]. Some authors
report that plasmids are not detectable at passages 11 to 20
(~80–120 days after transfection) in the vast majority of the
colonies tested [8]. We failed to detect EBNA1 DNA in all
iPSCs cell lines at passages 7 to 9 (~74–88 days after
transfection) (Fig. 3C), indicating that all exogenous
Fig. 3 Expression of pluripotency marker genes and absence of
reprogramming plasmids in the iPSC lines. Representative RT-PCR
and PCR analyses for pluripotent cell markers and reprogramming vectors
is shown. As a negative control, GAPDH amplification was also performed
without reverse transcription. Total RNA and DNAwas isolated from iPSC
clones established with either Lipofectamine 3000 (lanes A-B), Neon (lanes
C-E), Nucleofector Transfection System (lanes F-H) and CytoTune®-iPS
Sendai Reprogramming Kit (lanes I-K). Results from hDF 107 (C, F, I),
hDF 137 (A, B, D, G, J) and hDF 119 (E, H, K) derived iPSCs are shown.
NANOG, REX, SOX, c-MYC and OCT3/4 gene fragments could be
amplified from 30 ng cDNA, and GAPDH was used a loading control
(a). Pluripotency genes expression was also assessed (b) in the
commercially available hESC H7 line (lanes M-N). PCR failed to amplify
plasmid DNA from both individual vectors (pCX-hUL) or EBNA-1
sequence from all vectors (c), as well as fragments from viral sequences
(d) suggesting that all exogenous reprogramming agents are lost during
iPSC passaging. DNA from early passages Sendai derived iPSCs was
used as positive control (lane L)
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reprogramming agents are lost during iPSC passaging.
iPSCs generated by the Sendai virus methodwere investigated
by PCR at passage 15, and failed to amplify viral genomes as
well (Fig. 3D).
The pluripotency of the iPSC lines UTA.11916.EURCSs,
UTA.137062.EURCSp, UTA.107016.EURCAp and
UTA.119024.EURCSp was verified by EB formation and
the EBs were shown to express at least one marker from each
of the three germ layers (endoderm, ectoderm and mesoderm)
(Fig. S2).
Genomic Integrity
Karyotypic abnormalities occur without notable differences in
hESCs and iPSCs, and are commonly observed as early as
three passages after derivation [15]. The maintenance of a
correct karyotype is crucial for the exploitation of pluripotent
stem cell lines in the clinical setting, to avoid flaws in the
reproducibility of the results but more importantly, to prevent
dysregulation of physiological pathways and cellular
processes related to tumorigenicity. The most common
karyotypic abnormalities in hESCs involve copy number var-
iations of whole chromosomes or of telomeric regions of chro-
mosomes [15, 16].
To detect chromosomal abnormalities in our lines, we
used a BACs-on-beads (BoBs) method employed for the
genetic evaluation of the products of conception, which
also has proven useful for the genetic characterization
of stem cell lines [17, 18]. The assay can detect arm-
specific aneuploidies in all 24 chromosomes in a single
assay and it is expected to cover most gross abnormal-
ities. We performed two technical replicates of three
different iPSC lines per method, and did not find any chromo-
somal rearrangements (Fig. 2B). It has been reported that most
abnormalities occur from passage 3 to ~120, with a ~ 10 %
chance of finding an aneuploidy line, with small fluctuations
depending on the method being used, possibly hinting at a
mutagenic role of the method itself [15, 19]. These reports
gather data from hundreds or thousands of cell lines and the
lack of chromosomal rearrangements in our experimental set-
ting could be due to the small number of lines analyzed or the
relatively low passage number. Our results suggest that very
low rates of karyotypic abnormalities are to be expected in
routine experiments when performing established
reprogramming protocols.
Efficiency of each method aside, we did not observe
method-specific differences or patterns at gene or protein
marker expression levels; all lines tested were also
Fig. 4 Immunocytochemical staining for pluripotency markers of
iPSCs colonies. The expression of pluripotency genes in the iPSC lines
was studied at the protein level by immunocytochemical staining. Images
are composite of DAPI (blue) and specific signal (red) for OCT-4, SOX2,
SSEA-4, TRA 1-60 and TRA 1-81 pluripotency markers. DAPI signal
alone is shown, as a reference for each staining, in the upper left corner
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karyotypically normal. This observation is in line with other
reports, which compared other methods for iPSCs production
[19, 20]. We produced and characterized a number of patient-
specific iPSC lines, which exceeds what is usually required for
experiments in a standard laboratory setting. With increasing
number of iPSC lines, or when culturing them for a longer
period of time, it can be expected that differences in the mark-
er expression or aneuploidies arise [15]. However, the
vast majority of the iPSC lines we produced expressed
a wide range of pluripotency markers at both gene and
protein levels, with a normal karyotype. We used non-
commercial hDFs from three different patients, and these
hDFs showed differences in the reprogramming efficiency,
consistent between methods. However, analyses from iPSCs
derived with different methods from the same patient were
fairly comparable.
Lipofectamine 3000 can be used in a wider number of lab-
oratories, as it does not require dedicated equipment but
reprogramming efficiencywas highly unreliable and extremely
dependent on the hDF intrinsic amenability to reprogramming.
Viral reprogramming is time-efficient but still poses questions
to the use of generated iPSCs in the clinical setting, requires
dedicated labware and hoods and forbids the use of custom
cocktails by using proprietary reagents. Electroporation, al-
though more time consuming and needing dedicated equip-
ment, allows an efficient production of iPSCs by rivalling with
viral efficiency.
Our results directly apply to hDF reprogramming and we
concentrate on comparing different reprogramming methods
as well as pointing out the individuality of each patients' cells
being reprogrammed. iPSCs can be produced from a large
variety of other somatic cells than hDFs like peripheral blood
mononuclear cells, keratinocytes, adipose cells or mesenchy-
mal stem cells, and further studies would be needed to com-
pare the efficiency of current methods to reprogram those
other cell types.
Conclusions
In this study we compared four methods, which use three
different approaches (virus-, electroporation- and chemical-
based) to deliver reprogramming factors to hDFs from three
patients and reprogram them to iPSCs.We showed that Sendai
virus method, as expected, achieved the overall highest
reprogramming rate. Electroporation-based methods followed
with Nucleofector performing better than Neon system in our
experimental conditions. Lipofectamine 3000 delivery
resulted in the lowest reprogramming rate and could
only generate iPSCs out of one of the three patient-
derived hDFs. Differences in reprogramming rates of
fibroblasts taken from different patients showed consis-
tency between methods. Finally, characterized iPSCs did
not reveal any significant differences in their morpholo-
gy, expression of pluripotency markers, karyotype or gene
expression profiles, regardless of the method employed.
Furthermore, they were free of the episomal vectors used in
the reprogramming.
Taken together, these results suggest that iPSCs col-
onies obtained with any of the methods tested here dis-
play the expected iPSCs-like phenotype, express a broad
range of pluripotency markers at both mRNA and protein
level and are free of the episomal reprogramming vectors.
Moreover, karyotypic abnormalities are expected to occur
with low frequency regardless of the reprogramming method
employed.
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